The effects of pentoxifylline in severe chronic obstructive pulmonary diseases

The effects of pentoxifylline on 6-minute walk test parameters in patients with pulmonary hypertension due to chronic obstructive pulmonary diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201202018889N1

Enrollment

Registered

2012-09-17

Start date

2010-11-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension due to COPD. Chronic Obstructive Pulmonary Disease, Unspecified,Other Secondary Pulmonary Hypertension

Interventions

Intervention 1: Pentoxifylline 400 mg tablets (Amin Pharmacuetical Company). Intervention 2: Placebo with identical appearance to that of pentoxyfylline and composed of methyl cellulose (Department of

Treatment - Drugs

Pentoxifylline 400 mg tablets (Amin Pharmacuetical Company).

Placebo with identical appearance to that of pentoxyfylline and composed of methyl cellulose (Department of Pharmaceutics, Shiraz School of Pharmacy, Shiraz University of Medical Sciences).

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Severe to very severe chronic obstructive pulmonary diseases (COPD) according to the Global initiative for chronic Obstructive Lung Disease (GOLD) criteria [forced expiratory volume in one sec (FEV1)/forced vital capacity (FVC)<.7], FEV1 of less than 50% of the relevant predicted value, and systolic pulmonary artery pressure (SPAP) greater than 40 mmHg measure by Color Doppler Echocardiography. Exclusion criteria: History of myocardial infarction or unstable angina pectoris in the previous month, congestive left heart failure, inability to walk due to musculoskeletal disorders for 6 minutes, symptomatic peripheral vascular disorders, systolic blood pressure more than 180 mmHg, diastolic blood pressure more than 120 mmHg before 6-minute-walk test, significant resting or exertional cardiac dysrhythmias.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Arterial Oxygen Saturation. Timepoint: Baseline , 6th week and 12th week after intervention. Method of measurement: Pulse Oximetry.;6-minute walk distance. Timepoint: baseline , 6th and 12th weeks of intervention. Method of measurement: 6-minute walk test by walking for 6 minutes.;Dyspnea severity index. Timepoint: baseline , 6th week and 12th week after intervention. Method of measurement: Borg scale questioner.	—

Measure

Time frame

Arterial Oxygen Saturation. Timepoint: Baseline , 6th week and 12th week after intervention. Method of measurement: Pulse Oximetry.;6-minute walk distance. Timepoint: baseline , 6th and 12th weeks of intervention. Method of measurement: 6-minute walk test by walking for 6 minutes.;Dyspnea severity index. Timepoint: baseline , 6th week and 12th week after intervention. Method of measurement: Borg scale questioner.

—

Secondary

Measure	Time frame
Heart Rate. Timepoint: Baseline , 6th week and 12th week after intervention. Method of measurement: Pulse Oximetry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeiyed Mohammad Ali Ghayumi

Department of Internal Medicine , shiraz medical school

ghayyoumim@sums.ac.ir+98 71 1235 1087

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026